

Title (en)
TRIAZINEONE COMPOUNDS FOR TREATING DISEASES DUE TO SARCOSYSTIS, NEOSPORA AND TOXOPLASMA

Title (de)
TRIAZINONEVERBINDUNGEN FÜR DIE BEHANDLUNG VON KRANKHEITEN VERURSACHT DURCH SARCOSYSTIS, NEOSPORA UND TOXOPLASMA

Title (fr)
COMPOSES DE TRIAZINEONE UTILISES POUR TRAITER LES MALADIES DUES AUX SARCOSYSTIS, NEOSPORA ET TOXOPLASME

Publication
EP 1140101 A1 20011010 (EN)

Application
EP 99966449 A 19991217

Priority

- US 9930284 W 19991217
- US 21871298 A 19981222

Abstract (en)
[origin: WO0037084A1] Disclosed herein is a method of treating therapeutically, or metaphylactically infected animals susceptible to, or infected animal suffering from parasitic neurologic or abortigenic diseases such as Sarcocystidae or Toxoplasmosis that are treatable with triazineone compounds by administering thereto a pharmaceutically effective amount of the compound, including a single high dose therapeutic treatment.

IPC 1-7
A61K 31/53; **A61P 33/02**

IPC 8 full level
A61K 31/53 (2006.01); **A61P 15/06** (2006.01); **C07D 251/34** (2006.01); **A61P 25/00** (2006.01); **A61P 33/02** (2006.01); **C07D 251/38** (2006.01)

CPC (source: EP KR)
A61K 31/53 (2013.01 - EP KR); **A61P 15/06** (2018.01 - EP); **A61P 25/00** (2018.01 - EP); **A61P 33/02** (2018.01 - EP)

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
WO 0037084 A1 20000629; AU 2198100 A 20000712; BR 9916417 A 20011106; CA 2356181 A1 20000629; CN 1331595 A 20020116; EP 1140101 A1 20011010; HK 1043065 A1 20020906; HU P0104716 A2 20020429; HU P0104716 A3 20031028; JP 2002532552 A 20021002; KR 20010080571 A 20010822; NZ 512476 A 20030829; ZA 200103919 B 20020515

DOCDB simple family (application)
US 9930284 W 19991217; AU 2198100 A 19991217; BR 9916417 A 19991217; CA 2356181 A 19991217; CN 99815013 A 19991217; EP 99966449 A 19991217; HK 02105041 A 20020705; HU P0104716 A 19991217; JP 2000589195 A 19991217; KR 20017006550 A 20010525; NZ 51247699 A 19991217; ZA 200103919 A 20010515